نتایج جستجو برای: rituximab

تعداد نتایج: 11050  

Journal: :JAMA neurology 2015
Su-Hyun Kim In Hye Jeong Jae-Won Hyun AeRan Joung Hyo-Jin Jo Sang-Hyun Hwang Sooin Yun Jungnam Joo Ho Jin Kim

IMPORTANCE Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the individual risk-benefit of therapy and making treatment decisions. OB...

Journal: :Turkish neurosurgery 2013
Guner Menekse Ergun Daglioglu Osman Arikan Nacar Ersin Polat Cagatay Ozdol Ali Dalgic Gulnur Take Ali Ihsan Okten Ahmet Deniz Belen

AIM In the present study, we investigate the neuroprotective effects of rituximab, a monoclonal antibody directed towards B cell mediated humoral immunity, on a rat spinal cord injury (SCI) model with immunohistochemical methods. MATERIAL AND METHODS Twenty-four rats were used for the study. Rats were divided as control, SCI, and rituximab-treated SCI groups. Intraperitoneal rituximab adminis...

2013
R Karbasi-Afshar S Taheri

Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the literature was performed to gather the available data on lymphoproliferative disorders occurring in he...

2017
Samo Rozman Iztok Grabnar Srdjan Novaković Ales Mrhar Barbara Jezeršek Novaković

AIMS Pharmacokinetic (PK) studies suggest that there is a room for improvement in clinical use of rituximab through more individualized treatment. The objective of this study was to characterize rituximab PK in 29 newly diagnosed patients with diffuse large B-cell lymphoma treated with rituximab in combination with cyclophosphamide, doxorubicin, vincristine and methylprednisolone every 3 weeks....

2011
Carlos E. Araya Vikas R. Dharnidharka

Recurrence of FSGS occurs in 30-40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with treatment response. We found 18 reports of 39 transplant recipients who received rituximab. By univar...

Journal: :World Journal of Surgical Oncology 2006
Badrudeen M Hussain N Geetha V Lali Manoj Pandey

BACKGROUND Hypoglycemia is a vary rare toxicity of rituximab. The exact mechanism of rituximab induced hypoglycemia is not clear. CASE PRESENTATION A 50 year old female presented with a left tonsillar non Hodgkin's lymphoma and was started on R-CHOP chemotherapy. Twenty four hours after the first rituximab infusion, she developed hypoglycemia which was managed by IV glucose infusion. CONCLU...

2013
Tamara Castillo-Trivino Dejana Braithwaite Peter Bacchetti Emmanuelle Waubant

BACKGROUND Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. OBJECTIVES To evaluate the efficacy and safety of rituximab for MS treatment. DATA COLLECTION Studies were selected if they were clinical trials, irrespective of the dosage or combination therapies. MAIN RESULTS Four studies w...

2016
Jason H. Williams Matthew M. Hutmacher Matthew L. Zierhut Jean‐Claude Becker Barry Gumbiner George Spencer‐Green Lisa A. Melia Kai‐Hsin Liao Matthew Suster Donghua Yin Ruifeng Li Xu Meng

AIMS To evaluate potential differences between PF-05280586 and rituximab sourced from the European Union (rituximab-EU) and USA (rituximab-US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity assessment of PF-05280586. METHODS A randomised, double-blind, pharmacokinetic similarity trial...

Journal: :Blood 2002
Andrea L Rose Barbara E Smith David G Maloney

Rituximab, a chimeric human immunoglobulin G(1) (IgG(1)) anti-CD20 monoclonal antibody has been shown to mediate cytotoxicity in malignant B cells via several mechanisms in vitro. These include direct antiproliferative and apoptotic effects, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC). Glucocorticoids (GCs) are often administered in conjunct...

Journal: :Science translational medicine 2011
Alessia Fornoni Junichiro Sageshima Changli Wei Sandra Merscher-Gomez Robier Aguillon-Prada Alexandra N Jauregui Jing Li Adela Mattiazzi Gaetano Ciancio Linda Chen Gaston Zilleruelo Carolyn Abitbol Jayanthi Chandar Wacheree Seeherunvong Camillo Ricordi Masami Ikehata Maria Pia Rastaldi Jochen Reiser George W Burke

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to end-stage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism. Rituximab not only recognizes CD20 on B lymphocytes, but might also bind sph...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید